"Real World" Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed / Refractory Multiple Myeloma: A Combined Study from the Greek, Czech and UK Databases

被引：0
|
作者：
Terpos, Evangelos
Maouche, Nadjoua
Minarik, Jiri
Katodritou, Eirini
Jenner, Matthew W.
Plonkova, Hana
Gavriatopoulou, Maria
Vallance, Grant
Pika, Tomas
Kotsopoulou, Maria
Kothari, Jaimal
Jelinek, Tomas
Kastritis, Eftathios
Aitchison, Robin
Dimopoulos, Meletios A.
Ramasamy, Karthik
Hajek, Roman
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3087
引用
收藏
页数：4
相关论文
共 50 条
  • [1] "REAL WORLD" DATA ON THE EFFICACY AND SAFETY OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A STUDY OF THE GREEK MYELOMA STUDY GROUP
    Terpos, E.
    Katodritou, E.
    Kotsopoulou, M.
    Ntanasis-Stathopoulos, I.
    Lampropoulou, P.
    Papadaki, S.
    Papathanasiou, M.
    Stoumbos, D.
    Gavriatopoulou, M.
    Repousis, P.
    Kastritis, E.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2017, 102 : 511 - 512
  • [2] Real World Data on the Efficacy and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program
    Varga, Gergely
    Nagy, Zsolt
    Kosztolanyi, Szabolcs
    Szomor, Arpad
    Schneider, Tamas
    Deak, Beata
    Wolf, Krisztina
    Plander, Mark
    Szendrei, Tamas
    Varoczy, Laszlo
    Illes, Arpad
    Batai, Arpad
    Peto, Monika
    Fabian, Janos
    Masszi, Tamas
    Mikala, Gabor
    BLOOD, 2017, 130
  • [3] Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program
    Varga, Gergely
    Nagy, Zsolt
    Demeter, Judit
    Kosztolanyi, Szabolcs
    Szomor, Arpad
    Alizadeh, Hussain
    Deak, Beata
    Schneider, Tamas
    Plander, Mark
    Szendrei, Tamas
    Varoczy, Laszlo
    Illes, Arpad
    Batai, Arpad
    Peto, Monika
    Mikala, Gabor
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (04) : 1615 - 1620
  • [4] Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
    M. Macro
    C. Hulin
    L. Vincent
    A. Charvet-Rumpler
    L. Benboubker
    C. Calmettes
    A.-M. Stoppa
    K. Laribi
    L. Clement-Filliatre
    H. Zerazhi
    F. Honeyman
    V. Richez
    F. Maloisel
    L. Karlin
    J. Barrak
    C. Chouaid
    X. Leleu
    Annals of Hematology, 2023, 102 : 2137 - 2151
  • [5] Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
    Macro, M.
    Hulin, C.
    Vincent, L.
    Charvet-Rumpler, A.
    Benboubker, L.
    Calmettes, C.
    Stoppa, A. -m.
    Laribi, K.
    Clement-Filliatre, L.
    Zerazhi, H.
    Honeyman, F.
    Richez, V.
    Maloisel, F.
    Karlin, L.
    Barrak, J.
    Chouaid, C.
    Leleu, X.
    ANNALS OF HEMATOLOGY, 2023, 102 (08) : 2137 - 2151
  • [6] REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA
    Ziff, M.
    Cheesman, S.
    Kyriakou, C.
    Mehta, A.
    Papanikolaou, X.
    Rabin, N.
    Wechalekar, A.
    Yong, K.
    Popat, R.
    HAEMATOLOGICA, 2017, 102 : 786 - 787
  • [7] Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
    Terpos, Evangelos
    Ramasamy, Karthik
    Maouche, Nadjoua
    Minarik, Jiri
    Ntanasis-Stathopoulos, Ioannis
    Katodritou, Eirini
    Jenner, Matthew W.
    Plonkova, Hana
    Gavriatopoulou, Maria
    Vallance, Grant D.
    Pika, Tomas
    Kotsopoulou, Maria
    Kothari, Jaimal
    Jelinek, Tomas
    Kastritis, Efstathios
    Aitchison, Robin
    Dimopoulos, Meletios A.
    Zomas, Athanasios
    Hajek, Roman
    ANNALS OF HEMATOLOGY, 2020, 99 (05) : 1049 - 1061
  • [8] Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
    Evangelos Terpos
    Karthik Ramasamy
    Nadjoua Maouche
    Jiri Minarik
    Ioannis Ntanasis-Stathopoulos
    Eirini Katodritou
    Matthew W. Jenner
    Hana Plonkova
    Maria Gavriatopoulou
    Grant D. Vallance
    Tomas Pika
    Maria Kotsopoulou
    Jaimal Kothari
    Tomas Jelinek
    Efstathios Kastritis
    Robin Aitchison
    Meletios A. Dimopoulos
    Athanasios Zomas
    Roman Hajek
    Annals of Hematology, 2020, 99 : 1049 - 1061
  • [9] Efficacy and safety of carfilzomib, lenalidomide, and dexamethasone versus ixazomib, lenalidomide, and dexamethasone in real world patients with relapsed/refractory multiple myeloma: KMM2004 study
    Kim, Do Young
    Shin, Ho-Jin
    Min, Chang-Ki
    Eom, Hyeon-Seok
    Jung, Jongheon
    Kim, Kihyun
    Lee, Jae Hoon
    Yoo, Kwai Han
    Lee, Ji Yun
    Byun, Ja Min
    Kim, Sung-Hyun
    Lee, Ji Hyun
    Cho, Hee Jeong
    Lee, Sang Min
    Do, Young Rok
    Park, Sungwoo
    Lee, Junglim
    Lee, Seung-Shin
    Kang, Hye Jin
    Park, Young Hoon
    Lim, Sung-Nam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S189 - S190
  • [10] Real-world comparison of Ixazomib, lenalidomide and dexamethasone vs lenalidomide and dexamethasone in relapsed and refractory multiple myeloma
    Minarik, Jiri
    Pika, Tomas
    Radocha, Jakub
    Jungova, Alexandra
    Straub, Jan
    Jelinek, Tomas
    Pour, Ludek
    Pavlicek, Petr
    Mistrik, Martin
    Brozova, Lucie
    Krhovska, Petra
    Machalkova, Katerina
    Jindra, Pavel
    Spicka, Ivan
    Plonkova, Hana
    Stork, Martin
    Bacovsky, Jaroslav
    Capkova, Lenka
    Sykora, Michal
    Kessler, Petr
    Stejskal, Lukas
    Heindorfer, Adriana
    Ullrychova, Jana
    Maisnar, Vladimir
    Hajek, Roman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E271 - E272
12345